Satakarni Makkapati

We are the biggest consumer of 6-APA, amoxi, everything in the country. Irrespective of that, we will produce it, and then we will consume it ourselves.

The 2027, 2028, which I always told, will be the inflection point in the biosimilars business where I expect about seven approvals in Europe and possibly a couple of approvals in the U.S. on the upside.

We will be cost competitive. We will be the last man standing. We would like to shape the market in a manner that we can sustain our efforts over a long term.

We expect 2028 would be the inflection year for the biosimilar business. The business will stabilize with about seven products in the regulated markets, both in Europe and possibly a couple of products in the U.S. by 2028.

Our pipeline now extends up to 2032, and I'm reasonably convinced about the progress we are making.

We have a settlement in place. Based on the settlement, we cannot launch now.

I am very optimistic about a product like Omalizumab, where we will be probably one of the four companies to vie for the U.S. and the European market.

I see 2026 as an inflection point for this business. For the hard yards that have been put in and the investment prudence that we have followed...

We need an anchor industry here, right? I mean, India needs a WuXi sort of a moment, to make sure that we have a contract manufacturing setup that can compete globally.